"Symptom Flare Up" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transient exacerbation of symptoms of an existing disease or condition.
| Descriptor ID |
D000067251
|
| MeSH Number(s) |
C23.550.291.937.500
|
| Concept/Terms |
Symptom Flare Up- Symptom Flare Up
- Flare Up, Symptom
- Flare Ups, Symptom
- Symptom Flare Ups
- Symptom Flaring Up
- Flaring Up, Symptom
- Flaring Ups, Symptom
- Symptom Flaring Ups
- Acute Symptom Flare
- Acute Symptom Flares
- Flare, Acute Symptom
- Flares, Acute Symptom
- Symptom Flare, Acute
- Symptom Flares, Acute
- Symptom Flareup
- Flareup, Symptom
- Flareups, Symptom
- Symptom Flareups
- Symptom Flare-up
- Flare-up, Symptom
- Flare-ups, Symptom
- Symptom Flare-ups
|
Below are MeSH descriptors whose meaning is more general than "Symptom Flare Up".
Below are MeSH descriptors whose meaning is more specific than "Symptom Flare Up".
This graph shows the total number of publications written about "Symptom Flare Up" by people in this website by year, and whether "Symptom Flare Up" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2021 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Symptom Flare Up" by people in Profiles.
-
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 03; 81(3):370-378.
-
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 11 03; 60(11):5379-5389.
-
Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. J Autoimmun. 2021 05; 119:102615.
-
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
-
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017 Mar; 76(3):534-542.